Chris Shibutani
Stock Analyst at Goldman Sachs
(2.80)
# 1,956
Out of 5,055 analysts
96
Total ratings
54%
Success rate
5.04%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $48.34 | +106.87% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $2.87 | +4.53% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $21.64 | -30.68% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $29.33 | +9.10% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $102.67 | +33.44% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $17.18 | +92.08% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $471.92 | -36.01% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $39.16 | +30.23% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $199.58 | -22.34% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $13.98 | -71.39% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.65 | +161.44% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,021.70 | -29.24% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $17.46 | +48.91% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $143.56 | +6.58% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $234.00 | -26.07% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $59.58 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $46.81 | +47.40% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $21.97 | -40.83% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $69.14 | -66.73% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $9.50 | +426.32% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $64.10 | -18.88% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.08 | +139.23% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $8.47 | +112.51% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $7.98 | +113.03% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.18 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.91 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.96 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $48.34
Upside: +106.87%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $2.87
Upside: +4.53%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $21.64
Upside: -30.68%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $29.33
Upside: +9.10%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $102.67
Upside: +33.44%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $17.18
Upside: +92.08%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $471.92
Upside: -36.01%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $39.16
Upside: +30.23%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $199.58
Upside: -22.34%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $13.98
Upside: -71.39%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.65
Upside: +161.44%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,021.70
Upside: -29.24%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $17.46
Upside: +48.91%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $143.56
Upside: +6.58%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $234.00
Upside: -26.07%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $59.58
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $46.81
Upside: +47.40%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $21.97
Upside: -40.83%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $69.14
Upside: -66.73%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $9.50
Upside: +426.32%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $64.10
Upside: -18.88%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.08
Upside: +139.23%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $8.47
Upside: +112.51%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $7.98
Upside: +113.03%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.18
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.91
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $4.96
Upside: -